Pretreatment with Haloperidol Reduces $^{123}$I-FP-CIT Binding to the Dopamine Transporter in the Rat Striatum: An In Vivo Imaging Study with a Dedicated Small-Animal SPECT Camera

Susanne Nikolaus, Christina Antke, Konstantin Kley, Markus Beu, Andreas Wirrwar, and Hans-Wilhelm Müller

Clinic of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, Germany

Synaptic dopamine is mainly regulated by presynaptic dopamine transporter (DAT) activity. We hypothesized that variations in synaptic dopamine are reflected by variations of DAT radioligand binding. The effect of haloperidol, which increases synaptic dopamine concentrations, was therefore assessed in the rat striatum using $^{123}$I-$N$-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ($^{123}$I-FP-CIT) as a DAT radioligand.

**Methods:** Striatal $^{123}$I-FP-CIT binding was measured in 24 rats under baseline conditions (no pretreatment) and at 1 h after injection of haloperidol or a vehicle (1 mg/kg) using a small-animal SPECT camera.

**Results:** Baseline equilibrium ratios ($V_3^{\pm}$) were 1.32 ± 0.24 (mean ± SD). After the haloperidol injection, $V_3^{\pm}$ decreased to 0.99 ± 0.38 (P$_{\text{2-tailed}}$ < 0.0001), corresponding to a mean reduction of DAT binding by 25%.

**Conclusion:** Our results indicate competition between the DAT ligand $^{123}$I-FP-CIT and synaptic dopamine elevated by haloperidol, suggesting that the assessment of $^{123}$I-FP-CIT binding may be suitable to study variations in synaptic dopamine in vivo.

**Key Words:** FP-CIT; haloperidol; dopamine transporter; molecular imaging; small-animal SPECT


DOI: 10.2967/jnumed.109.061952

**Abstract**

Antipsychotic drugs such as the neuroleptic haloperidol are known to increase the synthesis and release of dopamine in the striatum and related mesolimbic structures (1–4). The suggested mechanism of action is the blockade of terminal presynaptic autoreceptors (2), leading to an abolition of feedback inhibition and, thus, to an increase of dopamine synthesis or release. Accordingly, compartmental analysis of 3-$N$-$^{11}$C-methylspiperone binding in pigs showed that the application of haloperidol led to antagonist binding to postsynaptic D$_2$ receptors and then to increased availability of endogenous dopamine, both resulting in a reduction of exogenous ligand binding to postsynaptic D$_2$ receptors in the striatum (5).

In this study, we pursue an analogous approach to the presynaptic constituent of the dopaminergic synapse using the tropane analog $^{123}$I-$N$-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ($^{123}$I-FP-CIT), which binds to the presynaptic dopamine transporter (DAT). Clinically, $^{123}$I-FP-CIT is used for the differential diagnosis between idiopathic Parkinson disease (Parkinsonian patients show a reduction of striatal DAT binding) and essential tremor (DAT is no different in individuals with essential tremor DAT vs. healthy controls) (6). If endogenous dopamine displaces exogenous radioligands or competes with them for presynaptic binding sites, this may have implications for DAT imaging studies in Parkinsonian subjects, who are treated with pharmacologic compounds that lead to an increased availability of dopamine in the synaptic cleft. Moreover, DAT binding is increasingly assessed in schizophrenic patients (7–16). Because neuroleptics such as haloperidol increase endogenous dopamine concentrations, radioligand binding to the DAT may be severely confounded in medicated schizophrenic patients.

In recent investigations, we demonstrated that DAT and D$_2$ receptor binding and blockade with methylphenidate and haloperidol, respectively, may be quantified in vivo in the rat striatum using a dedicated small-animal SPECT device (17–20). Additionally, it was shown that increases of synaptic dopamine as induced by methylphenidate may be assessed by quantifying D$_2$ receptor binding successively under pre- and posttreatment conditions (18). Here we investigate the effect of haloperidol, that is, the increase of synaptic dopamine on $^{123}$I-FP-CIT binding to the presynaptic DAT. Striatal DAT binding was measured in the rat under baseline conditions and at 1 h after pretreatment with haloperidol or a vehicle.
MATERIALS AND METHODS

Animals

DAT imaging studies were performed on 24 adult male Wistar rats (TVA, Heinrich-Heine University) weighing 442 ± 51 g (mean ± SD). On 3 other animals, images of bone metabolism, soft-tissue perfusion, and brain perfusion were acquired to delineate the striatal and cerebellar target regions, as previously published (17,20). Animals were maintained under standard laboratory conditions, with food and water freely available. The study was approved by the regional authority; it was performed in accordance with the Principles of Laboratory Animal Care (21) and the German Law on the Protection of Animals.

SPECT Camera

The small-animal tomograph (TierSPECT; Central Institute for Electronics [ZEL]) used in this study was described in detail elsewhere (22). The tomographic spatial resolution (full width at half maximum) of this camera was 3.4 mm for 123I (distance, 30 mm), and the sensitivity was 16 cps/MBq. Data were acquired in a 128 x 128 matrix (pixel width and slice thickness, =0.664 mm). Reconstruction was performed using an iterative ordered-subset expectation maximization algorithm (3 iterations, 4 subsets per iteration). No postfiltering procedure was applied. Attenuation correction was implemented, assuming a uniformly attenuating medium (linear attenuation coefficient, 0.10 cm−1).

Experimental Protocol

In all animals, DAT binding was assessed under baseline conditions (no treatment) and after pretreatment with haloperidol or vehicle. Injections were performed in randomized order, 10 ± 7 d apart. For baseline measurements, animals were intraperitoneally administered a mixture of ketamine hydrochloride (0.9 mL/kg; Ketavet [Pharmacia Mammal]); xylazine hydrochloride (0.4 mL/kg; Rompun [Bayer]) (concentration, 100 mg/mL) and ketamine hydrochloride (0.9 mL/kg; Ketavet [Pharmacia Mammal]) (concentration, 100 mg/mL). For the administration of haloperidol, 13 rats were measured twice; 7 rats also underwent a third measurement after pretreatment with haloperidol. Thereby, of the 20 rats that were subjected to both the baseline measurement and the measurement after pretreatment with haloperidol, 13 rats were measured twice; 7 rats also underwent a third measurement after pretreatment with vehicle.

For SPECT measurements, animals were positioned in a custom-built head holder (Institute of Medicine) to ensure reproducible positioning of the animals. Previous investigations on rats have shown that equilibrium of 123I-FP-CIT binding is reached at 2 h after injection, with the ratio of specific-to-nonspecific striatal uptake remaining stable through the following 4 h (25). Thus, SPECT measurements were started 2 h after radioligand application. Imaging data were acquired for 60 min in a step-and-shoot mode over a circular orbit in angular steps of 6° (60 projections, 60 s/projection), using a 65-mm radius of rotation. The 15% energy window was centered on the 159-keV γ-photopeak of 123I.

Imaging of head and neck bone metabolism, head and neck soft-tissue perfusion, and brain perfusion was performed as previously described using 99mTc-3,3-diphosphono-1,2-propa-decarboxylic acid (99mTc-DPD) (Tecsecs; CIS Diagnostik), 99mTc-tetrofosmin (Myoview; Amersham Buchler), and 99mTc-hexamethylpropylene-amine oxide (99mTc-HMPAO) (Ceretec; Amersham Buchler) as radiotracers (17,20). Imaging data were recorded as described above. The 15% energy window was centered on the 140-keV γ-photopeak of 99mTc.

Evaluation

Imaging data were evaluated using the Multi-Purpose-Imaging-Tool (Advanced Tomo Vision GmbH) as previously described (17,20). Briefly, target and reference regions were identified using sets of fusion images (99mTc-DPD–99mTc-tetrofosmin, 99mTc-DPD–99mTc-HMPAO, and 99mTc-DPD–123I-FP-CIT), allowing the detection of extracerebral anatomic landmarks such as the cranium, orbitae, and Harderian glands and the localization of the respective regions relative to the sites of specific accumulation of metabolism and perfusion markers. Maximum striatal and cerebellar counting rates (counts per pixel) were determined on coronal slices. Thereby, cerebellar counting rates were obtained in an elliptic region approximately 15 mm posterior to the frontal cortex, corresponding anatomically to the rat cerebellum (26). Additionally, the position of the cerebellum was verified visually with 99mTc-DPD–123I-FP-CIT fusion images.

The equilibrium ratio of the distribution volumes of the specific and the nonspecifically bound compartment (V′′ = V′/V2) was computed as an estimate for the binding potential (27). V′′ can be obtained as (V′/V2) − 1, with V′ denoting the total tissue equilibrium volume of distribution, equal to the sum of V2 and V3. If it is assumed that the equilibrium concentrations of free and nonspecifically bound ligand are the same across brain regions, V2 may be inferred from a region devoid of the target receptor (e.g., cerebellum), and V′′ in the striatum is obtained as V′′/(V′′(cerebellum)) − 1.

Statistical Analysis

For baseline and treatment conditions, striatal V′′ values were obtained from radioactivity concentrations (counts per pixel) in striatal target and cerebellar reference regions. Left and right striatal radioactivity concentrations were averaged. Cerebellar counting rates were normalized to the injected radioactivity (MBq) divided by the weight of the respective animal (g). The normal distribution of data was ascertained for each condition with the nonparametric Kolmogorov–Smirnov test (0.394 < P < 0.993).

Striatal V′′ values were compared between pretreatment conditions (baseline, pretreatment with haloperidol, and pretreatment with vehicle) with both 1-way ANOVA and paired t tests (2-tailed). Moreover, to test for possible influences of haloperidol on nonspecific binding (e.g., due to effects on perfusion) cerebellar counting rates were compared between pretreatment conditions (baseline, pretreatment with haloperidol, and pretreatment with vehicle) with the paired t test (2-tailed).

1148 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 50 • No. 7 • July 2009
RESULTS

A typical example of cerebral $^{123}$I-FP-CIT accumulation is shown in Figure 1. Figure 1A displays a characteristic coronal slice of a rat’s brain measured under baseline conditions. Prominent is the radioligand accumulation in the paired striatum. Figure 1B shows the $^{123}$I-FP-CIT accumulation in the same rat after pretreatment with haloperidol. Reduction of striatal $^{123}$I-FP-CIT binding is evident.

Striatal $^{123}$I-FP-CIT binding data of all investigated animals are presented in Figure 2.

Under the baseline condition and after pretreatment with a vehicle ($n = 10$; paired $t$ test, 2-tailed, $P = 0.360$) was observed. The differences between pretreatment with haloperidol and both baseline levels and levels under a vehicle were significant (baseline vs. haloperidol: $n = 20$; paired $t$ test, 2-tailed, $P < 0.0001$; and haloperidol vs. vehicle: $n = 7$, paired $t$ test, 2-tailed, $P = 0.010$).

Group comparisons between baseline levels and levels under pretreatment with haloperidol were also performed separately for the 13 rats undergoing 2 investigations and the 7 rats undergoing 3 investigations. The difference between baseline condition and pretreatment with haloperidol remained significant, irrespective of the number of investigations (2 measurements: paired $t$ test, 2-tailed, $P = 0.005$; and 3 measurements: paired $t$ test, 2-tailed, $P = 0.018$).

Decreases of DAT binding were observed in 16 of 20 animals (32% ± 19%), and increases of DAT binding were shown in 4 of 20 animals (5.4% ± 2.8%).

Cerebellar uptake values of $^{123}$I-FP-CIT were 13,561 ± 2,847 ($\text{counts/pixel} \times \text{MBq} / \text{g}$; baseline), 11,666 ± 4,375 (vehicle), and 15,078 ± 4,405 (haloperidol; data not shown). Differences between baseline and pretreatment with haloperidol and between baseline and pretreatment with vehicle were not significant ($P = 0.309$ and 0.271, respectively).

DISCUSSION

In this in vivo imaging study, pretreatment with haloperidol (1 mg/kg) induced a mean reduction of 25% of striatal $^{123}$I-FP-CIT binding relative to baseline, suggesting a competition between $^{123}$I-FP-CIT and endogenous dopamine.

Among the methodologic issues that warrant consideration are the use of ketamine as an anesthetic and the use of ethanol as a solvent for haloperidol. It may be dismissed, however, that the effect on $^{123}$I-FP-CIT binding was due to anesthesia, because animals were subjected to the same anesthesia protocol in both control and treatment conditions. Furthermore, in the present investigation, ethanol did not

![FIGURE 1. Characteristic slices of rat head under baseline conditions (A) and after pretreatment with haloperidol (B). Images show $V_3''$ values within cerebral outline. Calculations were performed using MATLAB (version 4.2c; The MathWorks Inc.). Reduction in striatal $^{123}$I-FP-CIT binding is evident and in this animal amounts to 54%.](image)

![FIGURE 2. $V_3''$ under baseline conditions and after pretreatment with haloperidol and vehicle. Circles represent individual animals. $V_3''$ values obtained for each rat on different days are connected by dotted lines. Investigated were total of 24 rats; thereby, 20 rats underwent baseline measurement and measurement after haloperidol challenge (solid lines), and 4 rats were subjected to baseline measurement and measurement after application of vehicle without assessment of DAT binding after challenge with haloperidol (dashed lines). $V_3''$ values were compared between conditions using paired $t$ test (2-tailed). Differences between baseline and haloperidol and between haloperidol and vehicle were significant. Exclusion of animal with highest $V_3''$ value at baseline (left column) leaves $P$ value for comparisons between baseline and haloperidol unaltered. Difference between baseline and pretreatment with vehicle remains nonsignificant ($P = 0.18$).](image)
significantly affect specific striatal DAT binding; thus, it may be excluded that the solvent on its own produced any effect by increasing dopamine concentrations in the synaptic cleft. Moreover, cerebellar radioactivity concentrations did not differ between baseline and pretreatment with ethanol or between baseline and pretreatment with haloperidol, demonstrating that, under the present experimental conditions, neither ethanol nor haloperidol exerted confounding effects on radioligand accumulation (e.g., by affecting cerebral perfusion).

Another issue is the time point of haloperidol administration relative to the time point of radioligand application. Previous in vivo microdialysis studies showed that maximum striatal dopamine concentrations are reached between 60 and 90 min after intraperitoneal or intravenous injection of haloperidol (1,3). In the present study, haloperidol was injected 60 min before 123I-FP-CIT application. Thus, the radioligand was administered at the time when maximum striatal dopamine concentrations were reached (1,3). 123I-FP-CIT requires 2 h to reach the state of equilibrium (25). Because striatal dopamine concentrations remain stable for 2 h (25), there is sufficient time for 123I-FP-CIT to reach a binding equilibrium in competition with endogenous dopamine. Moreover, previous investigations have shown that the ratio of specific-to-nonspecific striatal 123I-FP-CIT uptake remains stable for 4 h (25). Therefore, a suitable time window for the assessment of 123I-FP-CIT binding in relation to increase of endogenous dopamine is between 2 and 3 h.

Furthermore, the possibility must be considered that either haloperidol or its metabolites directly competed with the increase of endogenous dopamine is between 2 and 3 h.

Our assumption that haloperidol induced an increase of synaptic dopamine. For one, the effect of haloperidol can be mediated by the D2 antagonist binding to terminal presynaptic autoreceptors. Autoreceptor blockade then leads to an abolition of feedback inhibition and thus to an increase of dopamine synthesis or dopamine release (2). Moreover, as a result of concurrent autoreceptor regulation, a downregulation of dopamine reuptake (in addition to an upregulation of dopamine release) has been also observed, which likewise leads to an increased availability of dopamine in the synaptic cleft (4). On the other side, haloperidol may bind to postsynaptic D2 receptors, with postsynaptic D2 receptor blockade also leading to an increased availability of endogenous dopamine via an indirect neuronal feedback mechanism (30). The lesion studies by Westerink and de Vries have shown that postsynaptic binding to dopaminergic nerve terminals is not involved in the neuroleptic-induced increase in dopamine release, which also holds for neuroleptic binding to D2 autoreceptors on soma and dendrites (31). Therefore, our results are most likely to reflect haloperidol-induced stimulation of dopamine release via the terminal presynaptic D2 autoreceptor binding site or inhibition of dopamine reuptake via the DAT binding site.

Third, our in vivo findings on rats are supported by previous in vivo and ex vivo studies, which provided evidence that the application of the dopamine-releasing agents amphetamine and L-3,4-dihydroxyphenylalanine may lead to a reduction of exogenous radioligand binding to the DAT (32,33). Findings are furthermore in line with evidence presented by the Parkinson Study Group (34), which demonstrated a greater (though nonsignificant) decrease in striatal 123I-FP-CIT binding in patients treated with levodopa, compared with placebo-treated controls. Results are of particular interest with regard to scientific investigations of DAT binding in Parkinsonian subjects receiving any treatment—be it antioxidative, neuroprotective, or surgical—that leads to increased availabilities of synaptic dopamine.

In vivo microdialysis studies in rats showed a 50% increase of endogenous dopamine after a 1 mg/kg dose of haloperidol (3). This increase of endogenous dopamine, in context with our findings, poses the question of whether an increase of dopamine of this order of magnitude is sufficient to enter into an effective competition with the exogenous DAT ligand. So far, to our knowledge, the dissociation constant of 123I-FP-CIT has not been experimentally determined. The Kᵢ value, however, is known and amounts to 3.5 nM under competition with GBR12909 (27). For dopamine, an inhibitory concentration of 50% of 3.7 nM (35) and Kᵢ values between 0.59 and 19 nM (36) were reported using GBR12909 and WIN 35,065 analogs, respectively, as competitors. However, Kᵢ values in the micromolar range also were obtained when unlabeled dopamine was used as a competitor (37). This merely allows for a tentative estimation of binding relations at the presynaptic terminal. If the affinities of exogenous and endogenous ligands lie within the same order of magnitude, it is conceivable that the observed 25% decrease of 123I-FP-CIT binding reflects a decrease...
25% increase of synaptic dopamine. If, however, the affinity of $^{123}$I-FP-CIT for the DAT is, for example, one order of magnitude higher than the affinity of dopamine, a 25% decrease of $^{123}$I-FP-CIT binding would reflect an increase of synaptic dopamine by 10-fold. This increase is not consistent with the findings of Pehek (3), who showed a 50% increase of endogenous dopamine using in vivo microdialysis. Thus, further investigations are needed that explicitly address the quantification of synaptic dopamine.

Recently, there has been growing interest in assessing DAT binding in schizophrenic patients. Results on striatal DAT binding in schizophrenic subjects have been inconsistent, with reports of either elevated (11,12), reduced (9,11,16), or unaltered (7,8,10,13–15) DAT binding. Interestingly, also in medicated patients, either unaltered (8), decreased (9, 16), or increased DAT binding (12) has been observed. Results are difficult to interpret because factors such as duration of illness and illness phase, which may vary between patients and between investigations, are likely to affect the regulation state of pre- and postsynaptic binding sites. Our findings, moreover, suggest that neuroleptic medication itself may confound presynaptic binding data. It is known that schizophrenic patients who are not responding to neuroleptic treatment may present with a high percentage of occupied D$_2$ receptors and, nevertheless, display no relief of symptoms (38). In the light of the present findings, it is conceivable that presynaptic autoreceptor or transporter function may be dysregulated in this subgroup of schizophrenic patients. In addition, in the present study haloperidol pretreatment did not induce a reduction of DAT binding in all of the investigated animals, underlining the importance of further investigation of haloperidol-induced effects on dopamine release and presynaptic binding sites in preclinical animal models or schizophrenic patients.

CONCLUSION

In this study, the effect of haloperidol on DAT binding was assessed in the rat striatum using $^{123}$I-FP-CIT as a radioligand. Pretreatment with a 1 mg/kg dose of haloperidol induced a 25% reduction of DAT binding relative to baseline. Results in the rat striatum are indicative of the competition between the dopamine transporter ligand $^{123}$I-FP-CIT and synaptic dopamine elevated by haloperidol and, thus, suggest that assessment of $^{123}$I-FP-CIT binding may be suitable to study variations in synaptic dopamine. This may be of particular interest for investigating the interrelation of synaptic dopamine function and DAT schizophrenia and other diseases known to be associated with presynaptic deficiencies, such as attention-deficit hyperactivity disorder and Parkinson disease.

REFERENCES


$^{123}$I-FP-CIT BINDING AFTER HALOPERIDOL • Nikolaus et al.


Pretreatment with Haloperidol Reduces \(^{123}\text{I}\)-FP-CIT Binding to the Dopamine Transporter in the Rat Striatum: An In Vivo Imaging Study with a Dedicated Small-Animal SPECT Camera

Susanne Nikolaus, Christina Antke, Konstantin Kley, Markus Beu, Andreas Wirrwar and Hans-Wilhelm Müller

Published online: June 12, 2009.
Doi: 10.2967/jnumed.109.061952

This article and updated information are available at:
http://jnm.snmjournals.org/content/50/7/1147

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml